Loading
A phase 2 trial of single dose of CNCT19 in acute lymphoblastic leukaemia, run by Juventas Cell Therapy Ltd., now recruiting.
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia is a phase 2 interventional study registered as NCT04684147 by Juventas Cell Therapy Ltd., with 100 participants planned, started 2020-12-24 and due to reach its primary completion in 2022-09-22. Interventions recorded: single dose of CNCT19.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Juventas Cell Therapy, Inaticabtagene autoleucel, CAR-T cell therapy, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Juventas Cell Therapy, Inaticabtagene autoleucel, CAR-T cell therapy and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CAR-T cell therapy, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/